Author

Bernardo Rapaport

Observed names: B Rapaport, Bernardo Rappaport

Observed institution: Memorial Sloan Kettering Cancer Center

OpenAlex ID: A5113659111

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · Tony S K Mok, Yi-Long Wu, et al. · The Lancet · 3,317

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

2018 · Kohei Shitara, Mustafa Özgüroğlu, et al. · The Lancet · 1,290

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families

2002 · N D Kauff, P Perez-Segura, et al. · Journal of Medical Genetics · 94

Works count: 3

Citation count: 4,701

H-index: 3

I10-index: 3